Pharmaceuticals & Therapeutics

P4ML joins the Orphan Therapeutics Accelerator to bring shelved cures to patients, leveraging a new non-profit model and expanding access to the MENA region.

Flush with cash and nearing major clinical milestones for its neuromuscular disease pipeline, Dyne Therapeutics is set to make its case to investors.

With sales rising and key FDA milestones met, Australian biotech Immuron resets its strategy, seeking partners to fund its promising infectious disease pipeline.

With a new CEO at the helm and a pivotal trial for its lead drug on the horizon, all eyes are on PureTech's upcoming investor conference presentation.

The diabetes tech firm secures major funding for innovation and acquisitions, using a savvy financial strategy to protect current shareholder value.

New FDA-cleared Persona PLUS technology promises to increase plasma yields per donor, tackling the growing global demand for life-saving therapies.

The biotech firm secures major funding to push its promising head and neck cancer drug, ficerafusp alfa, toward regulatory approval and commercial launch.

A new Ontario program is giving breast cancer patients access to a life-changing drug a year sooner, setting a potential new standard for Canada.

The tech firm announced progress on a major health contract, but with its stock near all-time lows, can this deal deliver a much-needed turnaround?

Kenai Therapeutics hires a Novartis M&A veteran as CBO, signaling an aggressive strategy to advance its groundbreaking iPSC cell therapy for Parkinson's disease.

A new study links daily mango and avocado to better vascular function, but what does the science—and the funding—really tell us about this fruity fix?

Fastest-growing US professional skincare brand HYDRINITY partners with VeraSeaCosmetics, bringing its regenerative science to France's $5.4B beauty scene.

Medtronic's diabetes arm hits the road for its IPO, seeking to raise up to $784M in a major test of investor appetite for specialized medtech firms.

After a pivotal trial failure, Alector will present its new strategy at a key health conference, focusing on its innovative brain-delivery platform.

Facing SEC delays, Aptose Biosciences secures an $11.1M lifeline from its acquirer, Hanmi, highlighting financial strain as the critical deal moves forward.

Cullinan Therapeutics heads to key investor conferences, ready to showcase its T-cell engager platform for both cancer and challenging autoimmune diseases.

With pivotal data imminent for its blockbuster hopeful AXPAXLI, Ocular Therapeutix faces a critical month of investor meetings amid commercial headwinds.

As Autolus heads to key investor conferences, its strong AUCATZYL® sales and deep pipeline face scrutiny against mounting losses and a curious PR misstep.

Apellis Pharmaceuticals reports its first profitable year on strong SYFOVRE and EMPAVELI sales, but faces pressure to maintain momentum amid competition.

New Phase 1b data for oral drug pociredir reveals a robust boost in fetal hemoglobin, as Fulcrum Therapeutics secures a financial runway into 2029.